{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:04:10Z","timestamp":1756425850144,"version":"3.44.0"},"reference-count":26,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,6,11]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Xp11.2 translocation renal cell carcinoma (TRCC) is a rare and aggressive variant of renal cell carcinoma (RCC) when presenting in adults. We report a case of a man in his early 40s who was diagnosed with stage III Xp11.2 TRCC and underwent radical nephrectomy. Seven months following the surgery, an adrenal nodule and bilateral pulmonary nodules were discovered. He underwent cryoablation of the adrenal nodule and systemic treatment with daily pazopanib. He displayed stable disease for approximately 6\u2009years. Following this period, multiple hospitalisations interrupted daily pazopanib therapy resulting in progression of disease. His regimen was then changed to ipilimumab and nivolumab, followed by current daily therapy with axitinib. The patient now shows stable disease in his 10th year after diagnosis. This case study demonstrates the efficacy of pazopanib for metastatic Xp11.2 TRCC and warrants further investigation to supplement the guidelines regarding the use of targeted therapy for TRCC.<\/jats:p>","DOI":"10.1136\/bcr-2021-243058","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T12:35:18Z","timestamp":1624624518000},"page":"e243058","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib"],"prefix":"10.1136","volume":"14","author":[{"given":"Cristian","family":"Solano","sequence":"first","affiliation":[{"name":"William Beaumont School of Medicine, Oakland University, Rochester, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrinjaya","family":"Thapa","sequence":"additional","affiliation":[{"name":"Internal Medicine, Beaumont Hospital, Royal Oak, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-9577","authenticated-orcid":false,"given":"Mohammad Muhsin","family":"Chisti","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, William Beaumont School of Medicine, Oakland University, Troy, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"2025082803565302000_14.6.e243058.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.11.035"},{"key":"2025082803565302000_14.6.e243058.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"2025082803565302000_14.6.e243058.3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200203000-00001"},{"key":"2025082803565302000_14.6.e243058.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1183"},{"key":"2025082803565302000_14.6.e243058.5","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31824f24a6"},{"key":"2025082803565302000_14.6.e243058.6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22346"},{"key":"2025082803565302000_14.6.e243058.7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318031ffff"},{"key":"2025082803565302000_14.6.e243058.8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41379-018-0051-5","article-title":"Rna sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations","volume":"31","author":"Wang","year":"2018","journal-title":"Mod Pathol"},{"key":"2025082803565302000_14.6.e243058.9","doi-asserted-by":"crossref","first-page":"e13584","DOI":"10.1097\/MD.0000000000013584","article-title":"Effective treatment of advanced alveolar soft part sarcoma with sunitinib: a case report","volume":"97","author":"Ye","year":"2018","journal-title":"Medicine"},{"key":"2025082803565302000_14.6.e243058.10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25512"},{"key":"2025082803565302000_14.6.e243058.11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.169"},{"key":"2025082803565302000_14.6.e243058.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4693"},{"key":"2025082803565302000_14.6.e243058.13","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/PAS.0b013e3182613d8f","article-title":"Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum","volume":"36","author":"Argani","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"2025082803565302000_14.6.e243058.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611406"},{"key":"2025082803565302000_14.6.e243058.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.5324"},{"key":"2025082803565302000_14.6.e243058.16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy454"},{"key":"2025082803565302000_14.6.e243058.17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5152\/tud.2018.40460","article-title":"Patterns of management of translocation renal cell carcinoma","volume":"44","author":"Al-Daghmin","year":"2018","journal-title":"Turk J Urol"},{"key":"2025082803565302000_14.6.e243058.18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0482-z"},{"key":"2025082803565302000_14.6.e243058.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.162"},{"key":"2025082803565302000_14.6.e243058.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502380200"},{"key":"2025082803565302000_14.6.e243058.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2855"},{"key":"2025082803565302000_14.6.e243058.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602312200"},{"key":"2025082803565302000_14.6.e243058.23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urology.2018.03.032","article-title":"Renal cell carcinoma associated with Xp11.2 Translocation\/TFE3 Gene-fusion: a long response to mammalian target of rapamycin (mTOR) inhibitors","volume":"117","author":"Rua Fern\u00e1ndez","year":"2018","journal-title":"Urology"},{"key":"2025082803565302000_14.6.e243058.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"2025082803565302000_14.6.e243058.25","first-page":"7345","article-title":"A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo","volume":"63","author":"Christensen","year":"2003","journal-title":"Cancer Res"},{"key":"2025082803565302000_14.6.e243058.26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3892\/mco.2017.1142","article-title":"A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy","volume":"6","author":"Nishimura","year":"2017","journal-title":"Mol Clin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:57:00Z","timestamp":1756378620000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,25]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bcr-2021-243058"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243058","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}